MaxCyte Reports 2025 Financial Results, Announces 2026 Revenue Guidance and Expansion in Cell Therapy Platform 1

MaxCyte Reports Q4 and Full Year 2025 Financial Results; Issues 2026 Guidance

Key Highlights and Insights for Investors

Q4 2025 Revenue: \$7.3 million, at the top end of previous guidance.
Full Year 2025 Revenue: \$33.0 million, also at the top end of preliminary guidance.
Cash Position: \$155.6 million in cash, cash equivalents, and investments as of December 31, 2025. The company expects to end 2026 with at least \$136 million.
2026 Revenue Guidance: \$30-32 million; Core revenue expected to be \$25-27 million, SPL Program-related revenue around \$5 million.
Operational Streamlining: Annual cash burn reduced by more than \$16 million; cost structure streamlined.

Detailed Financial Performance

Q4 2025 vs Q4 2024

Total revenue decreased by 16% compared to Q4 2024.
Core business revenue (instruments, PAs, consumables, assay services, licenses): \$6.8 million, down 22% YoY.
SPL Program-related revenue: \$0.5 million, up from \$0.1 million YoY.
Gross margin: 78% (Non-GAAP margin also 78%); improved from 74% last year but down from 84% on adjusted basis.
Operating expenses: \$16.9 million, down from \$19.3 million YoY.
Net loss: \$9.6 million (improved from \$10.6 million loss in Q4 2024).
EBITDA (non-GAAP): Loss of \$10.2 million, improved from \$11.8 million loss YoY.
Stock-based compensation: \$0.7 million (significantly reduced from \$3.1 million YoY).

Full Year 2025 vs 2024

Total revenue: \$33.0 million, down 15% from \$38.6 million in 2024.
Core business revenue: \$29.6 million, down 9% YoY.
SPL Program-related revenue: \$3.4 million, down from \$6.1 million YoY (reflects headwinds from select SPL customers, including a 15% reduction in business from the largest customer).
Gross margin: 81% (Non-GAAP margin also 81%), compared to 82% GAAP and 84% Non-GAAP in 2024.
Operating expenses: \$78.7 million, down from \$82.7 million in 2024.
Net loss: \$44.6 million (higher than \$41.1 million loss in 2024).
EBITDA: Loss of \$47.6 million, slightly worse than \$46.9 million loss YoY.
Stock-based compensation: \$9.2 million, down from \$13.1 million YoY.
Goodwill impairment: \$3.6 million and restructuring expense: \$3.1 million for 2025.
Cash and equivalents: \$155.6 million, up from \$90.3 million last year.
Installed base of instruments grew to 857 (from 760 in 2024).
Number of SPLs: 32 (up from 28 in 2024), including 13 programs in clinic and 1 commercial program.
Core revenue generated by SPL clients: 47% of core revenue (down from 55% in 2024).

2026 Outlook

Revenue guidance: \$30-32 million, with core revenue expected at \$25-27 million and SPL Program-related revenue at ~\$5 million (including \$3 million from milestone payments and \$2 million from commercial royalties).
MaxCyte expects to end 2026 with at least \$136 million in cash, cash equivalents and investments.
Anticipates supporting up to four therapies in Phase III by end of 2026; already received a milestone payment for one therapy.
Continues to expand SPL portfolio, with four new SPLs signed in 2025.
Growth focus in 2026: Sales pipeline expansion, ExPERT electroporation platform, SeQure assay services, and new ExPERT DTx discovery platform launched in early 2026.
\$4 million core revenue headwind from select SPL customers expected to persist in 2026.

Strategic and Operational Insights

Reduction in purchases and leases from largest SPL customer (-15%), expected to stabilize in H2 2026 and potentially grow from new base.
Continued cost control and cash burn reduction, improving financial resilience.
Installed instrument base and SPL programs continue to grow, supporting potential future revenue.
MaxCyte’s technology and partnerships position it well in the expanding cell and gene therapy market.
Received milestone payments and expects increased royalties in coming years as therapies advance phases.

Balance Sheet Snapshot (as of Dec 31, 2025)

Total assets: \$202.5 million (down from \$239.5 million YoY).
Total liabilities: \$31.0 million (down from \$33.2 million YoY).
Total stockholders’ equity: \$171.5 million (down from \$206.3 million YoY).
Cash and cash equivalents: \$20.1 million; short-term investments: \$83.0 million; non-current investments: \$52.6 million.
Operating lease liabilities: \$17.9 million.

Potential Price Sensitive Information

Revenue declines: Both Q4 and full year revenues decreased substantially, primarily due to weakness in SPL customer activity, especially from the largest SPL partner.
Cash burn improvement: Annual cash burn reduced by \$16 million, with further cost controls and restructuring underway.
Guidance for 2026: Indicates continued headwinds but expects stabilization and growth in SPL-related revenue. Revenue guidance is lower than prior years, which could impact investor sentiment.
Milestone payments and royalties: Anticipated increase in milestone and royalty payments as partnered therapies progress, a potential catalyst for future revenue acceleration.
Expansion of SPL portfolio: Four new SPL agreements signed in 2025, increasing future clinical and commercial opportunities.
Reduction in stock-based compensation: A notable decrease from prior years, supporting a leaner cost structure.
Goodwill impairment and restructuring: Charges taken in 2025, reflecting strategic refocusing and cost management.
Strong cash position: Despite losses, the company maintains a robust balance sheet to support investments and operations.
Phase III therapies: By end 2026, MaxCyte expects to support up to four therapies in Phase III, with milestone payments already received—a potential significant value driver.

Conclusion

MaxCyte’s latest financial results reflect continued challenges in revenue growth due to SPL customer headwinds, particularly from its largest partner. However, management’s focus on cost control, cash burn reduction, and strategic expansion of its SPL portfolio, as well as the launch of new platforms, position the company for longer-term success in the cell and gene therapy market. The company’s robust balance sheet and anticipated milestone payments from advancing therapies provide support amid near-term revenue softness. Investors should closely monitor customer activity, clinical progress of partner programs, and the company’s ability to execute on its 2026 guidance as these factors could materially impact share value in the coming quarters.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own due diligence and consult with a professional advisor before making any investment decisions. All forward-looking statements are subject to risks and uncertainties as outlined in MaxCyte’s SEC filings.